Guselkumab maintenance treatment improves health-related quality of life in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR maintenance study

被引：0

作者：

Bressler, B. ^{[1
]}

Peyrin-Biroulet, L. ^{[2
,3
]}

Afif, W. ^{[4
]}

Samaan, M. A. ^{[5
]}

Wei, S. C. ^{[6
]}

Yarandi, S. ^{[7
]}

Germinaro, M.

Mistry, P. ^{[8
]}

Han, C. ^{[9
]}

Allegretti, J. R. ^{[10
]}

Lichtenstein, G. R. ^{[11
]}

机构：

[1] Univ British Columbia, Gastroenterol, Vancouver, BC, Canada

[2] Univ Lorraine, Inserm, NGERE, F-54000 Nancy, France

[3] Grp Hosp Prive Ambroise Pare Hartmann Paris IBD Ct, Gastroenterol, Nancy, France

[4] McGill Univ Hlth Care, Div Gastroenterol, Montreal, PQ, Canada

[5] Guys & St Thomas NHS Fdn Trust, Inflammatory Bowel Dis Unit, London, England

[6] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan

[7] Janssen Res & Dev LLC, Immunol, Spring House, PA USA

[8] Janssen Res & Dev LLC, Biostat, Spring House, PA USA

[9] Janssen Res & Dev LLC, Patient Reported Outcomes, Spring House, PA USA

[10] Harvard Med Sch, Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA

[11] Univ Penn, Gastroenterol, Philadelphia, PA USA

来源：

JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷

关键词：

D O I：

10.1093/ecco-jcc/jjae190.1343

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P1169

引用

页码：i2133 / i2135

页数：3

共 50 条

[31] Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study
Louis, E.
Panaccione, R.
Parkes, G.
Peyrin-Biroulet, L.
Ferrante, M.
Hisamatsu, T.
Siegmund, B.
Kalabic, J.
Levine, P.
Neimark, E.
Wallace, K.
Chen, S.
Cheng, L.
Duan, W. R.
Armuzzi, A.
Biederman, L.
Loftus, E.
Melmed, G.
Schreiber, S.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I10 - I12
[32] The Efficacy of Induction Treatment With Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Induction Study Results at Week 12 by Prior Advanced Therapy History
Bressler, Brian
Peyrin-Biroulet, Laurent
Allegretti, Jessica R.
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Shipitofsky, Nicole
Miao, Ye
Zhang, Hongyan
Bortlik, Martin
Hlavaty, Tibor
Fujii, Toshimitsu
Feagan, Brian G.
Sands, Bruce E.
Dignass, Axel
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S806 - S807
[33] Cumulative response to guselkumab through week 24 of induction in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study
Rubin, D.
Sands, B.
Lichtenstein, G.
Baker, T.
Huang, K. H.
Germinaro, M.
Miao, Y.
Zhang, H.
Nancey, S.
Allegretti, J.
Feagan, B.
Hisamatsu, T.
Panes, J.
Dignass, A.
Bressler, B.
Peyrin-Biroulet, L.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1722 - I1723
[34] Cumulative Response to Guselkumab Through Week 24 of Induction in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
Rubin, David T.
Sands, Bruce E.
Lichtenstein, Gary R.
Baker, Thomas
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Miao, Ye
Zhang, Hongyan
Nancey, Stephane
Allegretti, Jessica R.
Feagan, Brian G.
Hisamatsu, Tadakazu
Panes, Julian
Dignass, Axel
Bressler, Brian
Peyrin-Biroulet, Laurent
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S672 - S673
[35] Impact of MMX® Mesalamine on Improvement and Maintenance of Health-Related Quality of Life in Patients with Ulcerative Colitis
Hodgkins, Paul
Yen, Linnette
Yarlas, Aaron
Karlstadt, Robyn
Solomon, Dory
Kane, Sunanda
INFLAMMATORY BOWEL DISEASES, 2013, 19 (02) : 386 - 396
[36] Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Suzuki, Yasuo
Motoya, Satoshi
Hanai, Hiroyuki
Hibi, Toshifumi
Nakamura, Shiro
Lazar, Andreas
Robinson, Anne Martin
Skup, Martha
Mostafa, Nael Mohamed
Huang, Bidan
Thakkar, Roopal
Watanabe, Mamoru
JOURNAL OF GASTROENTEROLOGY, 2017, 52 (09) : 1031 - 1040
[37] RISANKIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 COMMAND
Schreiber, Stefan
Panaccione, Remo
Parkes, Gareth C.
Peyrin-Biroulet, Laurent
Ferrante, Marc
Hisamatsu, Tadakazu
Siegmund, Britta
Kalabic, Jasmina
Levine, Phillip
Neimark, Ezequiel
Wallace, Kori
Chen, Su
Cheng, Ling
Duan, W. Rachel
Armuzzi, Alessandro
Biedermann, Luc
Loftus, Edward V.
Melmed, Gil
Louis, Edouard
GASTROENTEROLOGY, 2024, 166 (05) : S238 - S238
[38] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 213 QUASAR STUDY RESULTS THROUGH WEEK 12
Allegretti, Jessica R.
Rubin, David T.
Bressler, Brian
Huang, Kuan-Hsiang G.
Shipitofsky, Nicole
Germinaro, Matthew
Zhang, Hongyan
Johanns, Jewel
Feagan, Brian
Sandborn, William J.
Sands, Bruce E.
Hisamatsu, Tadakazu
Lichi, Gary R.
Lichtenstein, Gary R.
Panes, Julian
Dignass, Axel
GASTROENTEROLOGY, 2022, 162 (07) : S963 - S964
[39] Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active Ulcerative Colitis: results from the Phase 3 QUASAR induction study
Sridhar, S.
Hart, A.
Venkat, S.
Huang, K. H. G.
Yarandi, S.
Germinaro, M.
Vetter, M.
Rubin, D. T.
Dignass, A.
Cua, D.
Freeman, T.
Waterworth, D.
Mcrae, B.
Verstockt, B.
Branigan, P.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i422 - i422
[40] Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
Sands, Bruce E.
Feagan, Brian G.
Gibble, Theresa Hunter
Traxler, Kristina A.
Morris, Nathan
Eastman, William J.
Schreiber, Stefan
Jairath, Vipul
Long, Millie D.
Armuzzi, Alessandro
CROHNS & COLITIS 360, 2023, 5 (04)

← 1 2 3 4 5 →